V-sling Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients
- Coordinator
- Cardiac Success Ltd, Israel
- Runs
- 1 May 2022 to 30 April 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €8.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190122502
What the project is doing
In the project's own words, from its summary on CORDIS.
Heart failure (HF) represents a major public health concern, affecting around 13M people worldwide. A major risk factor for HF is a myocardial infarction, which causes ventricular remodelling, during which the ventricle enlarges, making the heart even less effective at pumping blood, and results in displacement of the papillary muscle. Progressive papillary muscle displacement leads to severe Functional Mitral Regurgitation in about 20% of the patients, the only ones currently receiving treatment because of the severity of the condition.
The remaining 80% of patients don’t experience severe FMR and are not considered for surgery: they will continue to suffer, and likely die since there is no therapeutic option available. Cardiac Success develops the V-sling system, a transcatheter ventricular repair device to improve cardiac function in HF patients. The objectives of the project are to finalize product optimization, complete V&V and pre-clinical testing, and perform the FIH study.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Cardiac Success Ltd | Yokneam Illit | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI